Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents

Dianne L. Newton, Hans J. Hansen, Huaitian Liu, Dale Ruby, Mihail S. Iordanov, Bruce E. Magun, David M. Goldenberg, Susanna M. Rybak

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Targeting CD22 on human B-cells with a monoclonal antibody conjugated to a cytotoxic RNAse causes potent and specific killing of the lymphoma cells in vitro. This translates to anti-tumor effects in human lymphoma models in SCID mice. RNA damage caused by RNAses could be an important alternative to standard DNA damaging chemotherapeutics. Moreover, targeted RNAses may overcome problems of toxicity and immunogenicity associated with plant or bacterial toxin containing immunotoxins.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume39
Issue number1-2
DOIs
Publication statusPublished - 2001

    Fingerprint

Keywords

  • Antibody
  • Apoptosis
  • Cancer
  • Immunotoxin
  • Ribonuclease

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Newton, D. L., Hansen, H. J., Liu, H., Ruby, D., Iordanov, M. S., Magun, B. E., ... Rybak, S. M. (2001). Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents. Critical Reviews in Oncology/Hematology, 39(1-2), 79-86. https://doi.org/10.1016/S1040-8428(01)00116-0